COVID Updates: Due to the increased spread of COVID, visitor restrictions have changed and medical-grade masks are now required in all Scripps facilities. See FAQs for details.

A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

Trial ID:
Darren Sigal, M.D.
This study will test the safety and effectiveness of OBI-3424. OBI-3424 is an investigational study drug given once every three weeks via intravenous (IV) infusion in patients with advanced solid tumor cancer. This is the first study using OBI-3424 in humans.

Inclusion Criteria

Patients must:
  • Be 18 years of age or older.
  • Be ambulatory and able to carry out work of a light or sedentary nature. For example, must be capable of performing light housework or office work.
  • Have tumor tissue collected from a previous or new biopsy to be submitted for eligibility analysis

Exclusion Criteria

Patients must not:
  • Be pregnant or nursing.
  • Have hepatocellular carcinoma.
  • Have a history of symptomatic brain disease.
  • Have had prior radiotherapy to more than 25% of the bone marrow.

Additional Info

  • All physician visits and study treatments will occur at Scripps Clinic Torrey Pines (Geisel Pavilion).
  • Participation in the study will last for up to 2 years.
  • Search for NCT03592264 on for additional information.

Contact Info:

  • Clinical Research Services